The United States Food and Drug Administration (FDA) recalled Zantac and other ranitidine-based drugs because N-Nitrosodimethylamine (NDMA) was found in tests of the medication. NDMA is known as a probable carcinogen.
Zantac is available in pills, syrups, and other digestible forms. The chemical interactions of ranitidine and NDMA within the body can contribute to the development of cancer. Intestinal cancer and colorectal cancer are two types of cancer that have been associated with the use of Zantac.
Intestinal Cancer Symptoms
Imaging tests are the most common method of intestinal cancer detection. People who are highly at risk for developing intestinal cancer — such as people with Crohn’s disease, celiac disease, or colonic polyps — may be regularly tested and have potential symptoms closely monitored by their doctors.
Intestinal cancer symptoms may include:
- Changes in bowel habits
- Blood in the stool or dark stool
- Abdominal pain and discomfort
- Constipation
- Gas
- Weight loss
- Anemia
- Fatigue
Colorectal Cancer Symptoms
Colorectal cancer manifests as polyps in the colon. Through screening, polyps may be detected prior to cancer development.
If colon polyps are detected before cancer develops or colorectal cancer is detected in the early stages, it can be treated with surgery, chemotherapy, radiation, and other methods.
People with colorectal cancer may exhibit the following symptoms:
- Diarrhea
- Constipation
- Changes in bowel habits
- Blood in the stool or dark stool
- Abdominal pain and discomfort
- Fatigue
- Weight loss
Is Zantac Carcinogenic?
The presence of NDMA in Zantac caused the FDA to order a recall of ranitidine drugs. Many people who use Zantac take the drug every day to manage the symptoms of heartburn, which can lead to dangerous levels of NDMA and potentially cancer development.
We can help you file a claim against the pharmaceutical companies and pursue the compensation you deserve.
